PromiCell, Inc. presents during JP Morgan's 2026 Healthcare Conference
-
World No.1 Sinner pulls out of Shanghai Masters to delay return
-
Ethiopia's Tigray rebels abandon regional capital as govt advances
-
Red Bull's Verstappen grabs pole position for Bahrain GP
-
Bulgaria's Tsar Samuel returns 'home' after 1,000 years
-
India beat Pakistan in blockbuster as golfer Kim wins 'crazy' gold
-
'Glad it's over': Kim powers to Games gold and military exemption
-
India beat arch-rivals Pakistan to win Asian Games cricket gold
-
After 11 World Cups, football finally comes home for one Indian fan
-
Ethiopia's Tigray rebels abandon regional capital as govt advances: journalist
-
Marc Marquez wins sprint at Japan MotoGP, Martin grabs pole
-
Tom Kim powers to Games gold and exemption from military service
-
Alcaraz fends off Arnaldi to reach Japan Open quarters
-
Split loyalties for Indian football fans at Brazil friendly
-
Antonelli tops times in final practice at Bahrain GP
-
India-Pakistan blockbuster brings cricket fever to Japan baseball field
-
Gauff digs deep to beat Osorio in China Open second round
-
Wong waiting on Rafa after winning Asian Games tennis gold
-
Fresh protests to hit Spain after housing measures defeated
-
With Russia next door and rising costs, Latvia goes to the polls
-
'He's here with me': Japan cycle queen dedicates gold to late brother
-
Penalty hero rues empty seats as Games hosts Japan win football gold
-
Japan Olympic chief says 'lot more' athletes at Games than expected
-
North Korea fires ballistic missile after Seoul's apology demand
-
Asian carmakers besting US rivals at home, China poised to strike
-
US regulator finds Boeing 737 MAX software bug 'not a safety concern'
-
Widgets & Web Offers All-Inclusive Investor Relations Websites for Public Companies, IPOs and SPACs
-
Ohtani 'managing' injuries as Dodgers launch MLB post-season
-
Adams named new US captain to 2030 World Cup
-
Botched US execution leaves murderer unconscious on ventilator: lawyers
-
China a better influence in Latin America than US: poll
-
Cornell rape case exposes sexual violence at US colleges
-
Judge pauses construction of border project in Texas national park
-
France held by Italy in Zidane's homecoming after Olise stunner
-
Belgium's De Bruyne fires double to sink Turkey, France held by Italy
-
Ethiopian pro-government militia claims Tigray airport as regional tensions spike
-
US jobs data boosts stocks as oil prices dip
-
Ohtani shaking off injuries as Dodgers launch MLB post-season
-
US Supreme Court to hear high-stakes climate case
-
Sea levels to rise in California as coastal wave surges up west coast
-
Trump expected to name intel chief Clayton as AI czar: reports
-
New rallies urged in France as protests disrupt over 730 schools
-
Argentina unveils passports-for-investment scheme
-
Djokovic survives China Open scare, Sabalenka starts strong
-
Brazil election debate chaos sparks censorship row
-
King Charles to evoke colonial 'darkest days' on Caribbean tour
-
England's Carse charged by cricket body over nightclub incident
-
Tesla shares jump after global car sales top estimates
-
Amazon vows $1 bn for data center towns, decries 'myths'
-
DR Congo Ebola outbreak killed more than 4,000: official figures
-
Oil prices drop on G7 fuel release, US jobs data boosts stocks
PromiCell, Inc. presents during JP Morgan's 2026 Healthcare Conference
MIAMI, FL / ACCESS Newswire / January 9, 2026 / PromiCell, Inc. (the "Company"), a clinical-stage cellular immunotherapy company uniquely positioned to advance potentially curative cell therapies for cancer patients, today announced that the Company's Chief Medical Officer, John Lee, MD, Ph.D., will present interim results of the Company's lead asset PRO CAR - 201A, a STEAP1 directed CAR T cell that is currently in the clinic as a first-in-human phase 1 trial for the treatment of metastatic castration-resistant prostate cancer (mCRPC), at Biotech Showcase 2026 in San Francisco, California on Monday, January 12, 2025 at 11:15 am PST at the Franciscan D (Ballroom Level).
About PromiCell, Inc.
PromiCell, is a clinical-stage cellular immunotherapy company with product candidates representing highly differentiated and novel CAR T and TCR T platforms to be developed across separate solid and hematologic types of cancer. Our pipeline of innovative products includes STEAP 1 CAR T cells, HA-1 TCR T cells and CD 33 CAR T cells, applicable for the treatment of patients with mCRPC, Ewing Sarcoma, recurrent leukemia and acute myeloid leukemia. Our next-generation chimeric antigen receptor CAR T cell therapies are designed to address key mechanisms of tumor escape, disease relapse, and immune evasion. Our scientists are pioneers in CAR T-cell therapy, united in a mission to outsmart cancer and deliver more cures for patients. Learn more at www.promicell.com.
Contact:
305-433-1287
[email protected]
SOURCE: Promicell
View the original press release on ACCESS Newswire
E.Ramalho--PC
